natgillin/translations-raw huggingface dataset:
After a 5 day treatment of repaglinide (2 mg x 3/day) in patients with a severe impaired renal function (creatinine clearance: 20-39 ml/min.), the results showed a significant 2-fold increase of the exposure (AUC) and half-life (t1/2) as compared to patients with normal renal function.
Nakon petodnevnoga liječenja repaglinidom (2 mg x 3/dan) u bolesnika s jako oštećenom bubrežnom funkcijom (klirens kreatinina: 20-39 ml/min), rezultati su pokazali značajno dvostruko povećanje izloženosti (AUC) i poluvijeka (t1/2) u usporedbi s bolesnicima s normalnom bubrežnom funkcijom.
After a 5 day treatment of repaglinide (2 mg x 3/day) in patients with a severe impaired renal function (creatinine clearance: 20-39 ml/min.), the results showed a significant 2-fold increase of the exposure (AUC) and half-life (t½) as compared to patients with normal renal function.
Nakon petodnevnoga liječenja repaglinidom (2 mg x 3/dan) u bolesnika s jako oštećenom bubrežnom funkcijom (klirens kreatinina: 20-39 ml/min), rezultati su pokazali značajno dvostruko povećanje izloženosti (AUC) i poluvijeka (t1/2) u usporedbi s bolesnicima s normalnom bubrežnom funkcijom.
After a 600 mg abacavir tablet dose, the mean (CV) abacavir Cmax was approximately 4.26 g/ml (28%) and the mean (CV) AUC was 11.95 g.h/ml (21%).
Nakon pojedinačne doze od 600 mg abakavira, srednja vrijednost Cmax abakavira iznosi približno 4,26 µg/ml (koeficijent varijacije 28%), a srednja vrijednost AUC 11,95 µg.h/ml (koeficijent varijacije 21%).
After a booster dose at 12 to 15 months of age, fever ≥ 38°C was reported in 50.0% of infants who received Prevenar (7-valent) and Infanrix hexa at the same time as compared to 33.6% of infants receiving Infanrix hexa alone.
Nakon docjepljivanja djece u dobi od 12 do 15 mjeseci, vrućica ≥ 38°C je bila prijavljena u 50,0% dojenčadi koja su primila Prevenar (7-valentni) i Infanrix hexa u isto vrijeme u usporedbi s 33,6% dojenčadi koja su primila samo Infarinx hexa.
After a dosage of 2 mg/kg a Tmax of 1 h (cats and dogs), a Cmax of 1,464 ng/ml (cats) and 615 ng/ml (dogs), and an AUC of 3,128 ng·h/ml (cats) and 2,180 ng·h/ml (dogs) is obtained.
Nakon doziranja od 2 mg/kg postiže se Tmax od 1 h (mačke i psi), Cmax od 1464 ng/ml (mačke) i 615 ng/ml (psi), i AUC od 3128 ng·h/ml (mačke) i 2180 ng·h/ml (psi).
After a few seconds, an aerosol mist will begin to flow into the aerosol chamber of the Zirela Nebuliser Handset.
Nakon nekoliko sekundi maglica aerosola će početi proticati kroz komoru naprave za inhalaciju Zirela Nebuliser Handset.
After a few seconds, an aerosol mist will begin to flow into the aerosol chamber of the Zirela Nebuliser Handset.
Nakon nekoliko sekundi maglica aerosola će početi protjecati kroz komoru naprave za inhalaciju Zirela Nebuliser Handset.
After a heart attack (myocardial infarction)
Nakon srčanog udara (infarkta miokarda)
After a mean follow up of 2 years, the trial met its primary safety endpoint demonstrating saxagliptin does not increase the cardiovascular risk in patients with type 2 diabetes compared to placebo when added to current background therapy.
Nakon srednjeg razdoblja praćenja od 2 godine, ispitivanje je postiglo primarnu mjeru ishoda za sigurnosti, dokazujući da saksagliptin kao dodatak trenutnom osnovnom liječenju ne povećava kardiovaskularni rizik u bolesnika sa šećernom bolešću tipa 2 u usporedbi s placebom.
After a median follow-up of 12 months, the hazard ratio (HR) for disease free survival (DFS) was 0.54 (95 % CI 0.44, 0.67) which translates into an absolute benefit, in terms of a 2-year disease-free survival rate, of 7.6 percentage points (85.8 % versus 78.2 %) in favour of the Herceptin arm.
Nakon medijana praćenja od 12 mjeseci, omjer hazarda (engl. hazard ratio, HR) za preživljenje bez simptoma bolesti (engl. disease-free survival, DFS) iznosio je 0,54 (95% CI 0,44; 0,67), što znači da je apsolutno povoljan u smislu dvogodišnjeg preživljenja bez simptoma bolesti s razlikom od 7,6 postotnih bodova (85,8 % naspram 78,2 %) u korist skupine liječene lijekom Herceptin.
After a median follow-up of 144 weeks, 25 % of subjects on the ZDV/3TC/ABC/EFV arm and 26 % on the ZDV/3TC/EFV arm were categorised as having virological failure.
Nakon razdoblja praćenja s medijanom od 144 tjedna, 25% ispitanika u terapijskoj grani ZDV/3TC/ABC/EFV i 26% u terapijskoj grani ZDV/3TC/EFV kategorizirano je kao skupina s virološkim neuspjehom.
After a median follow-up of 32 weeks, the tritherapy with the three nucleosides ZDV/3TC/ABC was shown to be virologically inferior to the two other arms regardless of baseline viral load (< or > 100 000 copies/ml) with 26 % of subjects on the ZDV/3TC/ABC arm, 16 % on the ZDV/3TC/EFV arm and 13 % on the 4 drug arm categorised as having virological failure (HIV RNA >200 copies/ml).
Nakon razdoblja praćenja s medijanom od 32 tjedna, trojna terapija s tri nukleozida ZDV/3TC/ABC pokazala se virološki inferiornom u odnosu na ostale dvije skupine, neovisno o inicijalnom virusnom opterećenju (< ili > 100 000 kopija/ml) s 26% ispitanika u terapijskoj skupini ZDV/3TC/ABC, 16% u terapijskoj skupini ZDV/3TC/EFV i 13% u skupini koja je primala 4 lijeka koji su kategorizirani je kao virološki neuspjeh (HIV RNA >200 kopija/ml).
After a median observation time of 25 months from randomization, maintenance therapy with MabThera resulted in a clinically relevant and statistically significant improvement in the primary endpoint of investigator assessed progression-free survival (PFS) as compared to observation in patients with previously untreated follicular lymphoma (Table 4).
Nakon medijana promatranja od 25 mjeseci od randomizacije terapija održavanja lijekom MabThera u bolesnika s prethodno neliječenim folikularnim limfomom dovela je do klinički i statistički značajnog poboljšanja u primarnoj mjeri ishoda, tj. preživljenju bez progresije bolesti (PFS) prema procjeni ispitivača, u usporedbi s opservacijskom skupinom (Tablica 4).
After a median observation time of 25 months from randomization, maintenance therapy with MabThera resulted in a clinically relevant and statistically significant improvement in the primary endpoint of investigator assessed progression-free survival (PFS) as compared to observation in patients with previously untreated follicular lymphoma (Table 5).
Nakon medijana promatranja od 25 mjeseci od randomizacije terapija održavanja lijekom MabThera u bolesnika s prethodno neliječenim folikularnim limfomom dovela je do klinički i statistički značajnog poboljšanja u primarnoj mjeri ishoda, tj. preživljenju bez progresije bolesti (PFS) prema procjeni ispitivača, u usporedbi s opservacijskom skupinom (Tablica 5).
After a median observation time of 31 months for patients randomised to the induction phase, R-CHOP significantly improved the outcome of patients with relapsed/refractory follicular lymphoma when compared to CHOP (see Table 6).
Nakon medijana vremena promatranja od 31 mjeseca za bolesnike randomizirane u indukcijsku fazu, R-CHOP je u usporedbi s CHOP-om znatno poboljšao ishod bolesti u bolesnika s relapsirajućim/refraktornim folikularnim limfomom (vidjeti Tablicu 6).
After a minimum of 5 seconds, pull the needle out of the skin while keeping the dose setting knob pressed down (3).
Nakon najmanje 5 sekundi, izvucite iglu iz kože i dalje držeći pritisnut gumb za podešavanje (3).
After a minimum of 60 months follow-up the cumulative rates for rash (14%), musculoskeletal pain (14%), headache (13%), fatigue (11%), nausea (10%), myalgia (7%), vomiting (5%), and muscle inflammation or spasms (5%) increased by  3%.
Nakon najmanje 60 mjeseci praćenja kumulativna stopa pojave osipa (14%), mišićno-koštane boli (14%), glavobolje (13%), umora (11%), mučnine (10%), mialgije (7%), povraćanja (5%) i upale mišića ili spazma (5%) povećala se za ≤ 3%.
After a minimum of 60 months follow-up, the cumulative discontinuation rates were 14% and 7%, respectively.
Nakon najmanje 60 mjeseci praćenja, kumulativna stopa prekida terapije bila je 14% u skupini bolesnika liječenih lijekom SPRYCEL odnosno 7% u skupini bolesnika liječenih imatinibom.
After a number of rounds of replication genomic instability can reach insupportable levels and result in cancer cell death, as cancer cells have a high DNA damage load relative to normal cells.
Nakon nekoliko replikacijskih ciklusa, genomska nestabilnost može poprimiti neodržive razmjere i dovesti do smrti karcinomske stanice, jer su karcinomske stanice visoko opterećene oštećenjem DNK u odnosu na normalne stanice.
After a one-hour intravenous infusion, asparaginase activity was detected for at least 15 days after the first treatment with Oncaspar.
Nakon jednosatne intravenske infuzije, aktivnost asparaginaze mogla se zabilježiti najmanje 15 dana nakon prvog liječenja Oncasparom.
After a single 100 mg dose of isavuconazole was administered to 32 patients with mild (Child-Pugh Class A) hepatic insufficiency and 32 patients with moderate (Child-Pugh Class B) hepatic insufficiency (16 intravenous and 16 oral patients per Child-Pugh class), the least square mean systemic exposure (AUC) increased 64% in the Child-Pugh Class A group, and 84% in the Child-Pugh Class B group, relative to 32 age- and weight-matched healthy subjects with normal hepatic function.
Nakon jednokratne doze od 100 mg izavukonazola primijenjene kod 32 bolesnika s blagim oštećenjem jetrene funkcije (Child-Pugh stadij A) i 32 bolesnika s umjerenim oštećenjem jetrene funkcije (Child- Pugh stadij B) (16 intravenski i 16 oralno u svakom Child-Pugh stadiju), srednja vrijednost sistemske izloţenosti (AUC) procijenjena metodom najmanjih kvadrata povećala se 64% u skupini Child-Pugh stadij A i 84% u skupini Child-Pugh stadij B u odnosu na 32 zdrave osobe s normalnom funkcijom jetre, usklaĎene po dobi i tjelesnoj teţini.
After a single 250 mg dose in subjects with severe renal impairment (CLcr <30 mL/min) not requiring peritoneal dialysis or haemodialysis, crizotinib AUC and Cmax increased by 79% and 34%, respectively, compared to those with normal renal function.
Nakon pojedinačne doze od 250 mg u bolesnika sa teškim oštećenjem bubrega (CLcr <30 mL/min) koje ne zahtjeva peritonealnu dijalizu ili hemodijalizu, AUC i Cmax je očekivano povećana 79% i 34%, u usporedbi sa bolesnicima normalne bubrežne funkcije.
After a single 400 mg oral dose of [14C]-sofosbuvir, sofosbuvir and GS-331007 accounted for approximately 4% and >90% of drug-related material (sum of molecular weight-adjusted AUC of sofosbuvir and its metabolites) systemic exposure, respectively.
Nakon jedne peroralne doze od 400 mg [14C]-sofosbuvira, sofosbuvir i GS-331007 činili su približno 4% odnosno > 90% sistemske izloženosti tvarima povezanima s lijekom (zbroj molekularnoj težini prilagođenog AUC sofosbuvira i njegovih metabolita).
After a single 50 mg dose of metoprolol, a CYP2D6 substrate, concomitant administration of repeated 127 mg twice daily doses of eliglustat resulted in a 1.5- and 2.1-fold increase in metoprolol Cmax and AUC, respectively.
Nakon jedne doze metoprolola od 50 mg, supstrata CYP2D6, istovremena primjena ponovljene doze eliglustata od 127 mg dva puta dnevno rezultirala je povišenjem Cmax i AUC metroprolola od 1,5 odnosno 2,1 puta.
After a single 800 mg oral dose of 14C-boceprevir, the most abundant circulating metabolites were a diasteriomeric mixture of ketone-reduced metabolites with a mean exposure approximately 4fold greater than that of boceprevir.
Nakon jednokratne peroralne doze od 800 mg 14C-boceprevira, u cirkulaciji je najzastupljenija bila dijastereoizomerska smjesa metabolita s reduciranim ketonima, s oko 4 puta većom srednjom izloženošću od boceprevira.
After a single dose of 14C-labelled telmisartan the glucuronide represents approximately 11 % of the measured radioactivity in plasma.
Nakon jedne doze 14C- označenog telmisartana glukuronid predstavlja oko 11 % mjerene radioaktivnosti u plazmi.
After a single dose of 14C-labelled telmisartan the glucuronide represents approximately 11 % of the measured radioactivity in plasma.
Nakon jedne doze 14C- označenog telmisartana glukuronid predstavlja oko 11% mjerene radioaktivnosti u plazmi.
After a single dose of 14C-labelled telmisartan the glucuronide represents approximately 11 % of the measured radioactivity in plasma.
Nakon jedne doze 14C- označenog telmisartana, glukuronid predstavlja oko 11% mjerene radioaktivnosti u plazmi.
After a single dose of 14C-labelled telmisartan the glucuronide represents approximately 11 % of the measured radioactivity in plasma.
Nakon jedne doze 14C-označenog telmisartana glukuronid predstavlja oko 11 % mjerene radioaktivnosti u plazmi.
After a single dose of 14C-labelled telmisartan the glucuronide represents approximately 11 % of the measured radioactivity in plasma.
Nakon jedne doze 14C-označenog telmisartana glukuronid predstavlja oko 11% mjerene radioaktivnosti u plazmi.
After a single dose of [14C] sirolimus in healthy volunteers, the majority (91.1%) of radioactivity was recovered from the faeces, and only a minor amount (2.2%) was excreted in urine.
Nakon jednokratne doze od [14C] sirolimusa u zdravih dobrovoljaca, veći dio (91,1%) radioaktivnosti pronađen je u stolici, a tek je u manjoj količini (2,2%) izlučen u urinu.
After a single dose of CE/bazedoxifene, baseline-adjusted total estrone (representing CE) is eliminated with a half-life of approximately 17 hours.
Nakon jednokratne doze KE/bazedoksifena ukupan estron po početnoj vrijednosti (predstavlja KE) eliminira se s poluživotom od otprilike 17 sati.
After a single dose of CE/bazedoxifene, bazedoxifene and baseline-adjusted total estrone were absorbed with a tmax of approximately 2 hours and 8.5 hours, respectively.
Nakon jednokratne doze KE/bazedoksifena, bazedoksifen i ukupan estron po početnoj vrijednosti bili su apsorbirani s Tmax koje iznosi od otprilike 2 sata odnosno 8,5 sati.
After a single dose of rotigotine, binding to melanin-containing tissues (i.e., eyes) in the pigmented rat and monkey was evident, but was slowly cleared over the 14-day observation period.
Nakon jedne doze rotigotina, u pigmentiranog štakora i majmuna je bilo evidentno njegovo vezanje za tkiva koja sadržavaju melanin (tj. oči), ali se nakon perioda promatranja od 14 dana postupno smanjilo.
After a single dose, the duration of analgesia was dose and clinical pain model dependent, and ranged from 6 to greater than 12 hours.
Nakon jednokratne doze, trajanje analgezije ovisilo je o dozi i modelu kliničke boli, a kretalo se u rasponu od 6 do više od 12 sati.
After a single intravenous administration of Pixuvri at 29 mg/kg and 38 mg/kg, immediate deaths were seen in mice (114 mg/m2, LD10).
Primijećena je trenutačna smrt u miševa nakon pojedinačne intravenske primjene Pixuvria u dozama od 29 mg/kg i 38 mg/kg (114 mg/m2, LD10).
After a single intravenous bolus administration in healthy subjects the total body clearance of palonosetron was 173 ± 73 ml/min and renal clearance was 53 ± ml/min.
U zdravih ispitanika, nakon jedne intravenske primjene u bolusu, ukupni tjelesni klirens palonosetrona iznosio je 173  73 ml/min a bubrežni klirens bio je 53  29 ml/min.
After a single intravenous bolus administration in healthy subjects the total body clearance of palonosetron was 173  73 ml/min and renal clearance was 53  29 ml/min.
U zdravih ispitanika, nakon jedne intravenske primjene u bolusu, ukupni tjelesni klirens palonosetrona iznosio je 173  73 ml/min a bubrežni klirens bio je 53  29 ml/min.
After a single intravenous dose of 10 micrograms/kg [14C]-palonosetron, approximately 80 % of the dose was recovered within 144 hours in the urine with palonosetron representing approximately 40 % of the administered dose, as unchanged active substance.
Nakon jedne intravenske doze od 10 mikrograma/kg [14C]-palonosetrona, otprilike 80% doze izluči se unutar 144 sata u mokraći, pri čemu palonosetron predstavlja približno 40% primijenjene doze kao nepromijenjena djelatna tvar.
After a single IV administration, the total body clearance of teriflunomide is 30.5 ml/h.
Nakon jednokratne intravenske primjene ukupan klirens teriflunomida iz tijela iznosio je 30,5 ml/h.
After a single oral dose of 0.4 mg meloxicam/kg a Cmax value of 0.81 µg/ml was reached after 2 hours.
Nakon jedne oralne doze od 0,4 mg meloksikama/kg vrijednost Cmax od 0,81 µg/ml postignuta je poslije 2 sata.
After a single oral dose of 500 mg bosutinib with food, the mean elimination half-life was approximately 34 hours, and the mean clearance (Cl/F) was 197 + 57 L/h.
Nakon jedne oralne doze od 500 mg bosutiniba s hranom, aritmetička sredina poluvijeka eliminacije bila je približno 34 sata, a aritmetička sredina klirensa (Cl/F) bila je 197 + 57 l/h.
After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmax values of 2.1 µg/ml and 2.7 µg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.
Nakon jedne supkutane doze od 0,5 mg meloksikama/kg, vrijednosti Cmax od 2,1 µg/ml postignute su nakon 7,7 sati u mladih goveda, a od 2,7 µg/ml nakon 4 sata u krava u razdoblju laktacije.
After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmax values of 2.1 µg/ml and 2.7 µg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.
Nakon jedne supkutane doze od 0,5 mg meloksikama/kg, vrijednosti Cmaxod 2,1 µg/ml postignute su nakon 7,7 sati kod mladih goveda, a od 2,7 µg/ml nakon 4 sata kod krava u razdoblju laktacije.
After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmaxvalues of 2.1 µg/ml and 2.7 µg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.
Nakon jedne supkutane doze od 0,5 mg meloksikama/kg, vrijednosti Cmax od 2,1 µg/ml postignute su nakon 7,7 sati u mladih goveda, a od 2,7 µg/ml nakon 4 sata u krava u razdoblju laktacije.
After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmaxvalues of 2.1 μg/ml and 2.7 μg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.
2.7 μg / ml postignute su nakon 7.7 sati u junadi odnosno 4 sata u krava u laktaciji.
After a single subcutaneous dose of 1 to 10 µg/kg romiplostim in ITP patients, the peak platelet count was 1.3 to 14.9 times greater than the baseline platelet count over a 2 to 3 week period and the response was variable among patients.
Nakon jedne supkutane doze od 1 do 10 µg/kg romiplostima u bolesnika s ITP-om, vršni broj trombocita bio je 1,3 do 14,9 puta veći nego početni broj trombocita tijekom 2 do 3 tjedna, a terapijski odgovor varirao je od bolesnika do bolesnika.
After a single subcutaneous dose of 25 mg Enbrel, the average maximum serum concentration observed in healthy volunteers was 1.65  0.66 g/ml, and the area under the curve was 235  96.6 ghr/ml
Prosječna maksimalna serumska koncentracija zabilježena u zdravih dobrovoljaca nakon jednokratne supkutane doze Enbrela od 25 mg iznosila je 1,65  0,66 g/ml, a površina ispod krivulje iznosila je 235  96,6 µg • h/ml.
After a single subcutaneous dose of 25 mg Enbrel, the average maximum serum concentration observed in healthy volunteers was 1.65  0.66 g/ml, and the area under the curve was 235  96.6 ghr/ml.
Prosječna maksimalna serumska koncentracija zabilježena u zdravih dobrovoljaca nakon jednokratne supkutane doze Enbrela od 25 mg iznosila je 1,65  0,66 g/ml, a površina ispod krivulje iznosila je 235  96,6 µg • h/ml.
After a single subcutaneous injection of Elonva, the maximum serum concentration of corifollitropin alfa is 4.24 ng/mL (2.49-7.21 ng/mL1) and is reached 44 hours (35-57 hours1) postdose.
Nakon jedne supkutane injekcije lijeka Elonva, maksimalna serumska koncentracija korifolitropina alfa iznosi 4,24 ng/ml (2,49-7,21 ng/ml1) i postiže se 44 sata (35-57 sati1) nakon primjene.
After a single topical application of the veterinary medicinal product, the actives were detected at various regions of the cat’s body, including the caudal region, within the first days of application, indicating distribution/movement from the site of application (between the head and shoulder blades) across the body of the animal.
U prvim danima nakon lokalne aplikacije proizvoda dokazana je aktivnost u raznim područjima uključujući područje repa, što govori u prilog izvrsne distribucije s mjesta primjene (između glave i lopatica).
After a subcutaneous administration of 1 mg/kg the systemic bioavailability is 69% in cats and 88% in dogs.
Nakon subkutane primjene od 1 mg/kg sistemska bioraspoloživost iznosi 69 % u mačaka i 88 % u pasa.
After a thorough assessment of the available data, there appears to be reasonable support for the possibility of a causal relationship between Xolair and systemic lupus erythematosus.
Nakon temeljite ocjene dostupnih podataka, čini se da postoje razumni dokazi mogućnosti uzročne povezanosti između Xolaira i sistemskog eritemskog lupusa.
After a year, the patients who took Daxas had an average increase of 40 ml while those given placebo had an average decrease of 9 ml.
Nakon godine dana kod bolesnika koji su uzimali Daxas zabilježeno je prosječno povećanje od 40 ml, dok je kod onih koji su uzimali placebo prosječno smanjenje iznosilo 9 ml.
After a year, there was a decrease of about two-thirds in the number of MS attacks in Tysabri-treated patients, in comparison with the patients who received placebo.
Nakon jedne godine broj napadaja povezanih s multiplom sklerozom u bolesnika liječenih lijekom Tysabri smanjio se za dvije trećine u usporedbi s bolesnicima koji su primali placebo.
After abdominal surgery and if TachoSil sticks to nearby tissues, it is possible that scar tissues can develop in the operated area.
Moguć je razvoj ožiljkastih tkiva na operiranom području nakon kirurškog zahvata u trbuhu te ako se TachoSil zalijepi za okolna tkiva.
After about 7 years, a 28% median reduction in IgG levels was observed, with 1.6% of subjects experiencing a decrease in IgG levels to below 400 mg/dl.
Nakon otprilike 7 godina, zamijećeno je smanjenje razine IgG protutijela s medijanom od 28%, a u 1,6% ispitanika je zabilježeno sniženje razine IgG ispod 400 mg/dl.
After about 8 hours, wash the area where Aldara cream was applied with mild soap and water.
Nakon isteka 8 sati operite područje koje je bilo prekriveno kremom blagim sapunom i vodom.
After about 8 hours, wash the area where Zyclara was applied with mild soap and water.
Nakon otprilike 8 sati, operite područje na koje je Zyclara nanešena blagim sapunom i vodom.
After absorption, 66% of pravastatin undergoes a first-pass extraction through the liver, which is the primary site of its action and the primary site of cholesterol synthesis and clearance of LDL- cholesterol.
Nakon apsorpcije 66% pravastatina prolazi ekstrakciju prvim prolaskom kroz jetru, koja je i primarno mjesto njegovog djelovanja i primarno mjesto sinteze kolesterola i klirensa LDL kolesterola.
After absorption, cinacalcet concentrations decline in a biphasic fashion with an initial half-life of approximately 6 hours and a terminal half-life of 30 to 40 hours.
Nakon apsorpcije, koncentracije sinakalceta smanjuju se u bifazičnom obliku s početnim poluvijekom od oko 6 sati i završnim poluvijekom od 30 do 40 sati.
After accidental ingestion of the highest recommended dose, vomiting, salivation and diarrhoea may occur, however these should resolve without treatment.
Nakon slučajnog gutanja najviše preporučene doze, mogu se javiti povraćanje, slinjenje i proljev, međutim, te se nuspojave povlače bez liječenja.
After accidental oral ingestion or overdose, neurological signs (most of which are transient) such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may occur in very rare cases.
Nakon nehotičnog peroralnog unosa ili predoziranja, neurološki simptomi (od kojih je većina prolazna) kao što su ataksija, generaliziran tremor, znakovi na očima (proširene zjenice, smanjen pupilarni refleks i nistagmus) te poremećaji disanja, slinjenje i povraćanje mogu se javiti u vrlo rijetkim slučajevima.